Centogene
Krishna Kumar Kandaswamy possesses extensive experience in bioinformatics, having held multiple senior roles at CENTOGENE since July 2014, including Vice President and Senior Director. Prior to this, Krishna contributed as a Postdoctoral researcher at the Max Planck Institute for Biology of Ageing, developing novel bioinformatics methods and genetic inventories. Educational background includes a PhD in Bioinformatics from the University of Luebeck and a B.Tech in Biotechnology from PSG College of Technology, along with a diploma in Chemical Technology. Additional professional experience includes work as a project manager and external consultant, focusing on machine learning, workflow development, and bioinformatics methodologies.
Centogene
2 followers
Centogene BV is a Germany-based company engaged in the rare disease market. It focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The Company provides the full spectrum of methods and technology for human genetics analysis. It develops a rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450, 000 patients representing around 115 different, which includes epidemiologic, phenotypic and genetic data that reflects a global population, as well as a biobank of patients' blood samples. In addition, it is active in the research and development products for human genetics. The Company operates in Germany and the United States.